Comparisons of baseline clinical and treatment profiles between patients with or without statin
| Factor | Statin use | |||
| Overall | No | Yes | P value | |
| N | 1039 | 583 | 456 | |
| Demographics | ||||
| Age (years), mean (SD) | 58.88 (15.49) | 54.69 (16.29) | 64.20 (12.56) | <0.001 |
| Gender, male | 598 (57.89%) | 342 (59.17%) | 256 (56.26%) | 0.37 |
| Risk factors and comorbidities | ||||
| BMI (kg/m2), mean (SD) | 30.89 (6.41) | 31.19 (6.35) | 30.12 (6.29) | 0.011 |
| Vit D level, median (IQR) | 27.85 (18.80, 40.00) | 26.20 (17.25, 40.15) | 30.30 (20.60, 40.00) | 0.11 |
| Troponin, mean (SD) | 0.91 (12.11) | 0.25 (1.99) | 1.65 (17.54) | 0.096 |
| Smoking, yes | 116 (11.16%) | 64 (10.98%) | 52 (11.40%) | 0.84 |
| Neurological symptoms | 275 (26.47%) | 152 (26.07%) | 123 (26.97%) | 0.78 |
| GI symptoms | 673 (64.77%) | 400 (68.61%) | 273 (59.87%) | 0.004 |
| Respiratory symptoms | 878 (84.50%) | 504 (86.45%) | 374 (82.02%) | 0.057 |
| Cardiac symptoms | 191 (18.38%) | 111 (19.04%) | 80 (17.54%) | 0.57 |
| Diabetes mellitus | 555 (53.42%) | 261 (44.77%) | 294 (64.47%) | <0.001 |
| Metabolic syndrome | 341 (46.84%) | 115 (31.94%) | 226 (61.41%) | <0.001 |
| Myocardial infarction | 70 (6.74%) | 28 (4.80%) | 42 (9.21%) | 0.006 |
| Stroke | 22 (2.12%) | 8 (1.37%) | 14 (3.07%) | 0.081 |
| Pneumothorax | 29 (2.79%) | 22 (3.77%) | 7 (1.54%) | 0.036 |
| GI bleeding | 32 (3.08%) | 17 (2.92%) | 15 (3.29%) | 0.72 |
| Thrombocytopenia | 123 (11.84%) | 66 (11.32%) | 57 (12.50%) | 0.56 |
| DVT | 568 (90.59%) | 305 (91.87%) | 235 (88.68%) | 0.21 |
| Eye symptoms | 3 (0.29%) | 2 (0.34%) | 1 (0.22%) | 1.00 |
| Hypertension | 540 (51.97%) | 232 (39.79%) | 308 (67.54%) | <0.001 |
| Hyperlipidemia | 156 (15.01%) | 45 (7.72%) | 111 (24.34%) | <0.001 |
| End-stage renal disease | 37 (3.56%) | 18 (3.09%) | 19 (4.17%) | 0.4 |
| Treatments | ||||
| Remdesivir | 668 (64.29%) | 380 (65.18%) | 288 (63.16%) | 0.51 |
| Dexamethasone | 811 (78.06%) | 461 (79.07%) | 350 (76.75%) | 0.41 |
| Prednisone | 223 (21.46%) | 125 (21.44%) | 98 (21.49%) | 1.00 |
| Hydroxychloroquine | 25 (2.41%) | 15 (2.57%) | 10 (2.19%) | 0.84 |
| Azithromycin | 561 (53.99%) | 310 (53.17%) | 251 (55.04%) | 0.57 |
| Aspirin | 332 (31.95%) | 97 (16.64%) | 235 (51.54%) | <0.001 |
| SSRI | 105 (10.11%) | 45 (7.72%) | 60 (13.16%) | 0.005 |
| Vit D therapy | 537 (51.68%) | 286 (49.06%) | 251 (55.04%) | 0.061 |
| Convalescent plasma | 91 (8.76%) | 52 (8.92%) | 39 (8.55%) | 0.91 |
| Monoclonal antibodies | 19 (1.83%) | 7 (1.20%) | 12 (2.63%) | 0.1 |
| Therapeutic anticoagulants/warfarin | 388 (38.88%) | 192 (37.28%) | 164 (38.95%) | 0.64 |
All data were expressed with N (%), otherwise explained.
BMI, body mass index; DVT, deep vein thrombosis; GI, gastrointestinal; SSRI, selective serotonin reuptake inhibitor.